47 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study https://www.zacks.com/stock/news/2246921/moderna-mrna-posts-upbeat-data-from-next-gen-covid-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246921 Mar 27, 2024 - Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges https://www.zacks.com/stock/news/2245553/bayer-bayry-banks-on-pipeline-progress-amid-challenges?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245553 Mar 25, 2024 - Bayer (BAYRY) relies on pipeline candidate elinzanetant and key drugs, Nubeqa and Kerendia, to drive growth amid pipeline and regulatory setbacks.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062 Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
GSK Outperforms Industry on Strength in Key Drugs & Vaccines https://www.zacks.com/stock/news/2243568/gsk-outperforms-industry-on-strength-in-key-drugs-vaccines?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2243568 Mar 20, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Top Research Reports for Microsoft, Coca-Cola & Accenture https://www.zacks.com/commentary/2241249/top-research-reports-for-microsoft-coca-cola-accenture?cid=CS-ZC-FT-research_daily-2241249 Mar 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Coca-Cola Company (KO) and Accenture plc (ACN).
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296 Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Pfizer (PFE) Gets EU Nod for Expanded Use of Pneumococcal Jab https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861 Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
Pfizer (PFE) Rises As Market Takes a Dip: Key Facts https://www.zacks.com/stock/news/2240265/pfizer-pfe-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2240265 Mar 13, 2024 - In the closing of the recent trading day, Pfizer (PFE) stood at $28.22, denoting a +0.75% change from the preceding trading day.
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run https://www.fool.com/investing/2024/03/10/have-2000-2-magnificent-stocks-ready-for-a-bull-ru/?source=iedfolrf0000001 Mar 10, 2024 - These stocks are trading down, but investors may be overlooking some important points.
These 3 Dividend Stocks Yield More Than 5% but Their Payout Ratios Are Over 100%. Are Dividend Cuts Coming? https://www.fool.com/investing/2024/02/21/these-3-dividend-stocks-yield-more-than-5-but/?source=iedfolrf0000001 Feb 21, 2024 - Relying on payout ratio alone can sometimes give investors a misleading picture of just how safe a dividend payment is.

Pages: 12345

Page 1>